Clinical Trials Logo

Clinical Trial Summary

Kidney diseases related to the immune system include, nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with connective tissue disorders. This study will allow researchers to admit and follow patients suffering from autoimmune diseases of the kidney. It will attempt to provide information about the causes and specific abnormalities associated with autoimmune kidney disease. Patients with kidney disease as a result of their immune system, and patients with diseases of the immune system who may later develop kidney disease, will be potential subjects for this study. Patients will undergo a history and physical examination, and standard laboratory test to more closely understand the causes, signs, symptoms, and responses to medication of these diseases. Based on these evaluations the patients may qualify as candidates for other experimental studies. At any time these patients may be asked to submit blood or urine samples for further research.


Clinical Trial Description

Study Description: This study evaluates participants with known or suspected immunologically-mediated kidney diseases, including but not limited to nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with other systemic or connective tissue disorders. Participants who have immunologically-mediated diseases with potential for kidney disease will be evaluated as well. Studies will include characterization of the clinical and laboratory features of these disorders, studies of natural history and complications, evaluation of responses to standard treatment. Blood and urine samples will be collected for immunological research conducted under this protocol. Objectives: Primary: -To collect samples and data obtained during standard clinical care that can be used to better understand rare forms of immunologically-mediated renal disorders, atypical renal disease that have not been fully characterized, and to allow for future research studies. Exploratory: - Characterize immunologically-mediated kidney diseases with regard to immune dysregulation, immune cell populations and role of complement activation. - Development of assays for novel antibodies. - Search for additional antibodies involved in the pathogenesis of membranous nephropathy and other glomerular diseases. - Assess changes in metabolic (e.g. vitamin D, lipids) and endocrine function (e.g. thyroid, adrenal function) during the evolution of the nephrotic state, during treatment and during remission. - Identify disease-causing memory B cells in participants with membranous nephropathy and correlation with membranous nephropathy relapse. Assess biological effects of phospholipase A2-receptor antibody epitope on the isolated memory B-cells. - Compare immune cell types, including B and T cell populations and cell type specific markers in the pathogenesis of immune-mediated kidney disease. - Compare changes in metabolome and proteome of urine and blood during the nephrotic syndrome, during treatment and in remission. - Computational analysis of renal structures which may provide predictive methods that would discriminate progressors from non-progressors beyond sclerosis in membranous nephropathy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00001979
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact Meryl A Waldman, M.D.
Phone (301) 451-6990
Email waldmanm@mail.nih.gov
Status Recruiting
Phase
Start date June 25, 1992

See also
  Status Clinical Trial Phase
Completed NCT02369354 - Transplant Social Worker Support for Live Kidney Donation in African Americans N/A
Not yet recruiting NCT02225782 - Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function Phase 4
Completed NCT00499187 - Fanconi Syndrome Due to ARVs in HIV-Infected Persons Phase 4
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Withdrawn NCT00585429 - Evaluation of Kidney Disease in Liver Transplant Recipients N/A
Completed NCT00183248 - Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients Phase 1/Phase 2
Completed NCT00001835 - Oxaliplatin in Cancer Patients With Impaired Kidney Function Phase 1
Completed NCT01331941 - A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function Phase 1
Terminated NCT00436748 - Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease Phase 3
Completed NCT01467466 - Prevention of Serious Adverse Events Following Angiography Phase 3
Completed NCT01235936 - Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia Phase 2
Completed NCT01947829 - Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY) N/A
Completed NCT01974999 - A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
Recruiting NCT01240564 - The Nephrotic Syndrome Study Network (NEPTUNE) N/A
Active, not recruiting NCT01228903 - Uric Acid and the Endothelium is CKD N/A
Completed NCT00734357 - Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients N/A
Completed NCT00781417 - Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease N/A
Completed NCT00096915 - Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis Phase 3
Completed NCT00093977 - Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease Phase 3
Completed NCT00094484 - Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis Phase 3